Parabilis Medicines PBLS
$27.44 −$0.19 (-0.67%)
Market closed · Nov 21, 9:10 am ET · Last extended-hours $27.44 0.00%
Open$27.07
Prev close$27.63
Day range$26.50 – $28.52
Volume1.25M
Market cap$3.44B
P/E (TTM)–
Dividend yield–
PBLS Stock News
Headlines matching Parabilis Medicines or the PBLS ticker, most recent first.
- Analysts Offer Insights on Healthcare Companies: Evolus (EOLS), Parabilis Medicines, Inc. (PBLS) and Acumen Pharmaceuticals (ABOS)
- BofA Securities Maintains Parabilis Medicines(PBLS.US) With Buy Rating, Announces Target Price $45
- Guggenheim Sticks to Its Buy Rating for Parabilis Medicines, Inc. (PBLS)
- Analysts Offer Insights on Healthcare Companies: Neumora Therapeutics, Inc. (NMRA), Celcuity (CELC) and Parabilis Medicines, Inc. (PBLS)
- Analysts Are Bullish on Top Healthcare Stocks: Parabilis Medicines, Inc. (PBLS), Cormedix (CRMD) Positive
- LifeSci Capital Maintains Parabilis Medicines(PBLS.US) With Buy Rating, Maintains Target Price $42
- BofA Securities Maintains Parabilis Medicines(PBLS.US) With Buy Rating
- A Quick Look at Today's Ratings for Parabilis Medicines(PBLS.US), With a Forecast Between $40 to $45
- Analysts Offer Insights on Healthcare Companies: Parabilis Medicines, Inc. (PBLS) and LENZ Therapeutics (LENZ)
- LifeSci Capital Initiates Parabilis Medicines(PBLS.US) With Buy Rating, Announces Target Price $42
- Parabilis Medicines, Inc. (PBLS) Receives a Buy From LifeSci Capital
- CCORF Initiates Parabilis Medicines(PBLS.US) With Buy Rating, Announces Target Price $39
- CCORF Maintains Parabilis Medicines(PBLS.US) With Buy Rating, Maintains Target Price $39
- H.C. Wainwright Maintains Parabilis Medicines(PBLS.US) With Buy Rating, Maintains Target Price $40
- H.C. Wainwright Maintains Parabilis Medicines(PBLS.US) With Buy Rating, Maintains Target Price $40
No comments yet — be the first to weigh in on PBLS.
Sign in to join the discussion.